VolitionRX (NYSEAMERICAN:VNRX) Issues Earnings Results

VolitionRX (NYSEAMERICAN:VNRX) released its quarterly earnings results on Thursday. The medical research company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.27), FiscalAI reports. The business had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.52 million.

VolitionRX Price Performance

NYSEAMERICAN:VNRX traded down $0.16 during mid-day trading on Thursday, reaching $2.20. The company’s stock had a trading volume of 103,794 shares, compared to its average volume of 262,034. The stock has a market cap of $17.80 million, a P/E ratio of -0.50 and a beta of 1.03. The company’s fifty day simple moving average is $3.35 and its two-hundred day simple moving average is $4.98. VolitionRX has a twelve month low of $2.01 and a twelve month high of $18.80.

Institutional Investors Weigh In On VolitionRX

Several hedge funds have recently modified their holdings of VNRX. Armistice Capital LLC boosted its position in shares of VolitionRX by 10.4% in the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after acquiring an additional 887,351 shares during the last quarter. Geode Capital Management LLC raised its stake in VolitionRX by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after purchasing an additional 85,816 shares during the period. Citadel Advisors LLC raised its stake in VolitionRX by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after purchasing an additional 135,775 shares during the period. Squarepoint Ops LLC acquired a new position in shares of VolitionRX in the 4th quarter valued at $34,000. Finally, Jane Street Group LLC purchased a new stake in shares of VolitionRX during the 4th quarter valued at $28,000. 8.09% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on VNRX shares. D. Boral Capital reissued a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th. HC Wainwright decreased their target price on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. Finally, Citigroup cut shares of VolitionRX to a “hold” rating in a research note on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, VolitionRX has a consensus rating of “Moderate Buy” and an average target price of $46.67.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.